ArticleEJVES vascular forum2025
Maintenance of Functionality Without Flushing of Totally Implantable Venous Access Devices: A Presentation of Clinical Cases.
Article in EJVES vascular forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to report experience of treating patients who underwent implantation of a long term totally implantable venous access device (TIVAD) that was not flushed. Methods: Patients who underwent TIVAD implantation between 1995 and 2016 were included in the present study. Sex, age, type of disease, indications, surgeon, device used, choice of venous access, type of procedure, morbidity, and follow up duration were considered. Results: Five hundred and forty-four patients underwent surgical TIVAD implantation. The most common type of disease was solid tumours (508 patients, 93,4%). In 503 patients, the TIVAD was implanted in the cephalic vein. Seven (1.3%) patients were diagnosed with tumour recurrence by an oncologist (5/7 male, median age 57 years). Four (57.1%) patients had recurrent colorectal cancer, and three (42.9%) had recurrent breast cancer. For several months, these patients did not return to the hospital for port flushing. None of these devices were heparinised for 18-24 months; however, no signs of occlusion were detected. Conclusion: This study shows that TIVAD can remain patent without flushing. Moreover, the lack of flushing could be economically advantageous and could provide relief for patients. Therefore, a larger study of this topic is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.